Showing results (191-200 of 324) with videos related to
Sort By:
Pageof 33
Diabetes|October 21, 2011
IL-21 is an antitolerogenic cytokine of the late-phase alloimmune responseAlessandra Petrelli, Michele Carvello, Andrea Vergani, et al.Journal for Immunotherapy of Cancer|February 16, 2021
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacyNina M Muñoz, Malea Williams, Katherine Dixon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.Cold Spring Harbor Molecular Case Studies|April 4, 2018
Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common originHannah C Beird, Chia-Chin Wu, Davis R Ingram, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2003
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigensGiao Q Phan, Christopher E Touloukian, James C Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2016
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung AdenocarcinomaYanyan Lou, Lixia Diao, Edwin Roger Parra Cuentas, et al.Frontiers in Immunology|August 22, 2017
A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating LymphocytesMarie-Andrée Forget, René J Tavera, Cara Haymaker, et al.Cancer Immunology Research|January 8, 2017
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 BlockadeCara L Haymaker, DaeWon Kim, Marc Uemura, et al.Cancer Immunology Research|April 3, 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research InstituteIra Mellman, Vanessa M Hubbard-Lucey, Matthew J Tontonoz, et al.Journal for Immunotherapy of Cancer|January 25, 2022
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primaryAhmad A Tarhini, Sandra J Lee, Aik-Choon Tan, et al.Pageof 33